Loading...

SNGX SOLIGENIX INC Business Restructuring 8-K Filing

SLGN

SNGX

SOLIGENIX INC

(SNGX)

2026 8-K

Shareholder Update

Stock Offering Agreement

Compliance Regained

Funding Announcement

FDA Grants Designation

Nasdaq Non-Compliance

Product Expansion

Bylaw Amendment

Loan Termination

Stock Sale Agreement

Warrant Inducement Agreement

Reverse Stock Split

Annual Meeting Adjournment

Compliance with NASDAQ Requ...

Delisting Notice

Annual Meeting of Stockholders

Meeting Adjournment

Annual Meeting Adjournment

Adjournment of Annual Meeti...

Accounting Firm Change

Securities Purchase Agreeme...

Director Compensation Polic...

Investment Agreement

Loan Agreement Amendment

External Links:

On April 28, 2026, Soligenix, Inc. announced that its Phase 3 FLASH2 trial for HyBryte™ in treating cutaneous T-cell lymphoma was halted for futility. The company aims to explore merger and acquisition options while continuing to evaluate dusquetide for Behçet’s Disease.

AI Assistant

SOLIGENIX INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.